Liza Y. Gelissen

Amsterdam, NH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Treatment satisfaction during personalized extended interval dosing of natalizumab in patients with multiple sclerosis.

Treatment satisfaction during personalized extended interval dosing of natalizumab in patients with multiple sclerosis.

Journal: Multiple sclerosis and related disorders

Published: April 30, 2026

Individual Variability of CD19+ B-Cell Repopulation in People With Multiple Sclerosis Treated With Extended Interval Dosing of Ocrelizumab.

Individual Variability of CD19+ B-Cell Repopulation in People With Multiple Sclerosis Treated With Extended Interval Dosing of Ocrelizumab.

Journal: European journal of neurology

Published: March 19, 2026

Clinical implications of natalizumab Fab-arm exchange in patients with multiple sclerosis.

Clinical implications of natalizumab Fab-arm exchange in patients with multiple sclerosis.

Journal: Frontiers in immunology

Published: January 26, 2026

No interferon-beta antibodies in natalizumab-treated multiple sclerosis patients with progressive multifocal leukoencephalopathy.

No interferon-beta antibodies in natalizumab-treated multiple sclerosis patients with progressive multifocal leukoencephalopathy.

Journal: Journal of the neurological sciences

Published: January 26, 2026

Author response to letter to the editor.

Author response to letter to the editor.

Journal: Journal of the neurological sciences

Published: December 19, 2025

Wearing-off symptoms persist in the majority of patients with multiple sclerosis after switching from natalizumab to ocrelizumab.

Wearing-off symptoms persist in the majority of patients with multiple sclerosis after switching from natalizumab to ocrelizumab.

Journal: Journal of the neurological sciences

Published: August 25, 2025

Safety and patient experiences with the natalizumab biosimilar in multiple sclerosis treatment.

Safety and patient experiences with the natalizumab biosimilar in multiple sclerosis treatment.

Journal: Multiple sclerosis and related disorders

Published: July 29, 2025

Accuracy of New John Cunningham Virus Antibody Assay in Natalizumab-Treated Patients With Multiple Sclerosis.

Accuracy of New John Cunningham Virus Antibody Assay in Natalizumab-Treated Patients With Multiple Sclerosis.

Journal: JAMA neurology

Published: March 31, 2025

Low natalizumab trough concentrations are associated with reduced seroconversion of the John Cunningham virus in natalizumab-treated patients with multiple sclerosis.

Low natalizumab trough concentrations are associated with reduced seroconversion of the John Cunningham virus in natalizumab-treated patients with multiple sclerosis.

Journal: Journal of neurology, neurosurgery, and psychiatry

Published: December 31, 2024

Pharmacokinetic Model-Informed Precision Dosing of Natalizumab in Multiple Sclerosis.

Pharmacokinetic Model-Informed Precision Dosing of Natalizumab in Multiple Sclerosis.

Journal: CPT: pharmacometrics & systems pharmacology

Published: October 22, 2024

Subcutaneous administration of natalizumab can lead to lower drug concentrations compared to intravenous administration.

Subcutaneous administration of natalizumab can lead to lower drug concentrations compared to intravenous administration.

Journal: Multiple sclerosis and related disorders

Published: April 11, 2024

Influence of personalized extended interval dosing on the natalizumab wearing-off effect - a sub-study of the NEXT-MS trial.

Influence of personalized extended interval dosing on the natalizumab wearing-off effect - a sub-study of the NEXT-MS trial.

Journal: Journal of the neurological sciences

Published: March 15, 2024

Showing 1-12 of 14

Last Updated: 09/26/2026